+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

CpG island methylator phenotype (CIMP) of colorectal cancer is best characterised by quantitative DNA methylation analysis and prospective cohort studies



CpG island methylator phenotype (CIMP) of colorectal cancer is best characterised by quantitative DNA methylation analysis and prospective cohort studies



Gut 55(7): 1000-1006



The concept of CpG island methylator phenotype (CIMP) is not universally accepted. Even if specific clinicopathological features have been associated with CIMP, investigators often failed to demonstrate a bimodal distribution of the number of methylated markers, which would suggest CIMP as a distinct subtype of colorectal cancer. Previous studies primarily used methylation specific polymerase chain reaction which might detect biologically insignificant low levels of methylation. To demonstrate a distinct genetic profile of CIMP colorectal cancer using quantitative DNA methylation analysis that can distinguish high from low levels of DNA methylation. We developed quantitative real time polymerase chain reaction (MethyLight) assays and measured DNA methylation (percentage of methylated reference) of five carefully selected loci (promoters of CACNA1G, CDKN2A (p16), CRABP1, MLH1, and NEUROG1) in 460 colorectal cancers from large prospective cohorts. There was a clear bimodal distribution of 80 microsatellite instability-high (MSI-H) tumours according to the number of methylated promoters, with no tumours showing 3/5 methylated loci. Thus we defined CIMP as having >or=4/5 methylated loci, and 17% (78) of the 460 tumours were classified as CIMP. CIMP was significantly associated with female sex, MSI, BRAF mutations, and wild-type KRAS. Both CIMP MSI-H tumours and CIMP microsatellite stable (MSS) tumours showed much higher frequencies of BRAF mutations (63% and 54%) than non-CIMP counterparts (non-CIMP MSI-H (0%, p<10(-5)) and non-CIMP MSS tumours (6.6%, p<10(-4)), respectively). CIMP is best characterised by quantitative DNA methylation analysis. CIMP is a distinct epigenotype of colorectal cancer and may be less frequent than previously reported.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 011908506

Download citation: RISBibTeXText

PMID: 16407376

DOI: 10.1136/gut.2005.082933


Related references

Correlation of pathologic features with CpG island methylator phenotype (CIMP) by quantitative DNA methylation analysis in colorectal carcinoma. American Journal of Surgical Pathology 30(9): 1175-1183, 2006

CpG island methylator phenotype-low (CIMP-low) colorectal cancer shows not only few methylated CIMP-high-specific CpG islands, but also low-level methylation at individual loci. Modern Pathology 21(3): 245-255, 2008

18q loss of heterozygosity in microsatellite stable colorectal cancer is correlated with CpG island methylator phenotype-negative (CIMP-0) and inversely with CIMP-low and CIMP-high. Bmc Cancer 7: 72, 2007

CpG island methylator phenotype-low (CIMP-low) colorectal cancer shows low-level methylation at individual loci. 2008

Molecular correlates with MGMT promoter methylation and silencing support CpG island methylator phenotype-low (CIMP-low) in colorectal cancer. Gut 56(11): 1564-1571, 2007

The CpG island methylator phenotype CIMP in colorectal cancer. 2013

The CpG island methylator phenotype (CIMP) in colorectal cancer. Gastroenterology and Hepatology from Bed to Bench 6(3): 120-128, 2013

CpG island methylator phenotype-low (CIMP-low) in colorectal cancer: possible associations with male sex and KRAS mutations. Journal of Molecular Diagnostics 8(5): 582-588, 2006

Correlation of -Catenin Localization with Cyclooxygenase-2 Expression and CpG Island Methylator Phenotype (Cimp) in Colorectal Cancer. Neoplasia 9(7): 569-577, 2007

Body size, physical activity and risk of colorectal cancer with or without the CpG island methylator phenotype (CIMP). Plos one 6(4): E18571, 2011

Correlation of beta-catenin localization with cyclooxygenase-2 expression and CpG island methylator phenotype (CIMP) in colorectal cancer. Neoplasia 9(7): 569-577, 2007

Evaluation of markers for CpG island methylator phenotype (CIMP) in colorectal cancer by a large population-based sample. Journal of Molecular Diagnostics 9(3): 305-314, 2007

Down-regulation of p21 (CDKN1A/CIP1) is inversely associated with microsatellite instability and CpG island methylator phenotype (CIMP) in colorectal cancer. Journal of Pathology 210(2): 147-154, 2006

Phase II study of nab-paclitaxel in refractory small bowel adenocarcinoma and CpG island methylator phenotype (CIMP)-high colorectal cancer. Annals of Oncology 30(3): 495, 2019

Phase II study of nab-paclitaxel in refractory small bowel adenocarcinoma and CpG island methylator phenotype (CIMP)-high colorectal cancer. Annals of Oncology 29(1): 139-144, 2018